SCHEMBL118345

SCHEMBL118345

CC1=NN(c2ccc(N)cc2)C(=O)C1

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.97
KMT2A Q03164 6/20 0.97
MEN1 O00255 5/20 0.97
ALDH1A1 P00352 5/20 0.97
KDM4E B2RXH2 5/20 0.97
RECQL P46063 1/20 0.97
TDP1 Q9NUW8 4/20 0.70
LMNA P02545 1/20 0.70
HTT P42858 1/20 0.70
GAA P10253 3/20 0.69
CYP1A2 P05177 1/20 0.69
CHRM2 P08172 1/20 0.69
CYP3A4 P08684 1/20 0.69
CHRM1 P11229 1/20 0.69
TSHR P16473 1/20 0.69
PTGS1 P23219 1/20 0.69
DRD3 P35462 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
APP P05067 7/20 0.66
POLB P06746 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8625650 0.98 MAPT (1.00) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL2203669 0.87 MAPT (0.77) MAPTKMT2AMEN1ALDH1A1KDM4E
Edaravone SCHEMBL19474814 0.85 MAPT (0.72) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL14600349 0.83 KMT2A (0.71) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL30425269 0.82 MAPT (0.68) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL16900694 0.82 MAPT (0.70) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL31420004 0.82 MAPT (0.70) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL3529446 0.82 MAPT (0.70) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL4257409 0.82 MAPT (0.70) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL4661670 0.82 MAPT (0.70) MAPTKMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109824740-B Method for interconversion between different pyrazolone reagent derivatives of reducing sugars 西北大学 2023-03-10 CN claimed
CN-109824740-B Method for interconversion between different pyrazolone reagent derivatives of reducing sugars 西北大学 2023-03-10 CN disclosed
US-20210128529-A1 DRUG CONTAINING PYRAZOLONE DERIVATIVE NOBELPHARMA CO., LTD. (JP) 2021-05-06 US disclosed
EP-2623101-B1 Piperidine and piperazine derivatives as autotaxin inhibitors MERCK PATENT GMBH (DE) 2021-04-21 EP disclosed
CN-112118839-A Pyrazolone derivative-containing drug 耐贝医药株式会社 2020-12-22 CN disclosed
EP-3666270-A1 DRUG CONTAINING PYRAZOLONE DERIVATIVE Nobelpharma Co., Ltd. (JP) 2020-06-17 EP disclosed
EP-1793821-B1 PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS MITSUBISHI TANABE PHARMA CORP (JP) 2018-10-31 EP disclosed
US-10004720-B2 Agent for preventing and/or treating ophthalmologic diseases MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-06-26 US disclosed
EP-3321255-A1 NOVEL THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) OR DISEASE ATTRIBUTABLE TO ALS Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed
US-20170273949-A1 AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-09-28 US disclosed
US-RE35801-E PYRAZOLONE DERIVATIVES MITSUBISHI CHEMICAL CORPORATION (JP) 1998-05-19 US disclosed
CN-1141291-A 4-(Arylaminomethylene)-2,4-dihydro-3-pyrazolones MERCK PATENT GMBH (DE) 1997-01-29 CN disclosed
EP-0743304-A1 4-(Arylaminomethylene)-2,4-dihydro-pyrazol-3-ones MERCK PATENT GmbH (DE) 1996-11-20 EP disclosed
EP-0540729-A1 BLOCKED FILTER DYES FOR PHOTOGRAPHIC MATERIAL AND PROCESS EASTMAN KODAK COMPANY (US) 1993-05-12 EP disclosed
EP-0208874-B1 PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS MITSUBISHI KASEI CORPORATION (JP) 1993-03-24 EP disclosed
WO-1992021064-A1 BLOCKED FILTER DYES FOR PHOTOGRAPHIC MATERIAL AND PROCESS EASTMAN KODAK COMPANY (US) 1992-11-26 WO disclosed
US-4857542-A INHIBITOR AGAINST LIPID PEROXIDATION MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1989-08-15 US disclosed
EP-0208874-A1 Prophylactic and therapeutic agent for circulatory disorders MITSUBISHI KASEI CORPORATION (JP) 1987-01-21 EP disclosed
US-3996282-A Water-soluble quaternary ammonium dyestuffs STERLING DRUG INC. (US) 1976-12-07 US disclosed
US-3935182-A Water-soluble quaternary ammonium heterocyclic azo dyestuffs STERLING DRUG INC. (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170273949-A1 AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES MITF, EYA3, AQP1 MAPT 2342/4885KMT2A 2873/4885MEN1 2887/4885
US-20210128529-A1 DRUG CONTAINING PYRAZOLONE DERIVATIVE CYP11B2, CYP3A5, DPYD MAPT 4271/4885KMT2A 1306/4885MEN1 3967/4885
US-10004720-B2 Agent for preventing and/or treating ophthalmologic diseases MITF, EYA3, AQP1 MAPT 2342/4885KMT2A 2873/4885MEN1 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.